Targeting SARS CoV2 (Indian isolate) genome with miRNA: An in silico study

Abstract

The newly identified SARS CoV2 has become a global pandemic since December 2019. Various researchers are trying to design a vaccine candidate against the virus. On the other hand, another group is focussing on repurposing approved or clinically tested drugs for treatment. However, there is always a search for alternative therapies. Thus, we propose an alternative approach apart from chemotherapy that is the usage of miRNA as novel antisense therapy to cure SARS CoV2 infected patients. To address the objective, miRNAs have been designed by targeting the genome of SARS CoV2 (Indian isolate). First, the open reading frames in the viral genome have been identified, and the proteins encoded by those open reading frames have been predicted. Using computational biology, several miRNAs have been designed and their probability to bind to a viral gene has been predicted. In addition, miRNA target mining in the host cell has been done to rule out the possibility of non-specific binding of the miRNAs. The miRNAs having the highest chances to bind to the viral genome have been converted into pre-miRNAs, and their interaction with dicer endoribonuclease has been studied by molecular docking. Results revealed that the pre-miRNAs interact with the RNAse III 2 domain of dicer. Thus, it is predicted that the pre-miRNAs after delivery to the infected host cell will be processed by dicer to generate mature miRNAs that will target the SARS CoV2 viral genome. Therefore, miRNA therapy can be an alternative approach for the treatment of SARS CoV2 infection. K E Y W O R D S dicer, miRNA, open reading frame, SARS CoV2 1 | INTRODUCTION SARS CoV2 is a positive-sense single-stranded RNA virus with a genome size of 29,903 nucleotides that consists of two untranslated regions (UTRs) at the 5 0 (265 nt) and 3 0 (229 nt) ends and 11 open reading frames (ORFs) that encode 27 proteins. The first ORF (ORF1/ab) (21,290 nucleotides) encodes 16 non-structural proteins (NSPS) such as replicase proteins pp1a of 4,405 amino acids

Mesenchymal Stem Cell-Derived Extracellular Vesicles in the Management of COVID19-Associated Lung Injury: A Review on Publications, Clinical Trials and Patent Landscape

“…Several in silico studies are being undertaken to investigate the miRNA that can potentially aid in COVID-19 management (Fig. 4 ) [ 84 – 86 ]. For instance, in silico analysis done by Schultz et al reported the capability of MSC-EVs miRNA to modulate the increased cytokines, cell death and coagulation disturbs caused by COVID-19 [ 87 ].…”